Compare COUR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | DNTH |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2021 | N/A |
| Metric | COUR | DNTH |
|---|---|---|
| Price | $8.45 | $44.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $12.36 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 2.4M | 780.0K |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $739,774,000.00 | $3,078,000.00 |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $6.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.09 | N/A |
| 52 Week Low | $5.76 | $13.37 |
| 52 Week High | $13.56 | $45.46 |
| Indicator | COUR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 65.78 |
| Support Level | $7.83 | $42.00 |
| Resistance Level | $8.00 | $45.46 |
| Average True Range (ATR) | 0.26 | 2.00 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 87.30 | 79.49 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.